Get started
Author

L. Vollmer

Observed names: L Vollmer, L.M. Vollmer, Lutz Michael Vollmer, Lutz Vollmer, Lutz-Michael Vollmer, Lutz‐Michael Vollmer, Vollmer, Lutz-Michael
Observed institution: University of Tübingen
OpenAlex ID: A5110530798
Economic evaluation of individualized nutritional support in medical inpatients: Secondary analysis of the EFFORT trial
2020 · Philipp Schuetz, Suela Sulo, et al. · Clinical Nutrition · 97
PDF
Cost savings associated with nutritional support in medical inpatients: an economic model based on data from a systematic review of randomised trials
2021 · Philipp Schuetz, Suela Sulo, et al. · BMJ Open · 76
PDF
A cost-effectiveness analysis of a hydration response technology dressing in the treatment of venous leg ulcers in the UK
2018 · Stefan Walzer, Daniel Dröschel, et al. · Journal of Wound Care · 18
PDF
A Cost Impact Analysis of clonoSEQ® as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
2021 · Stefan Walzer, Sebastian Krenberger, et al. · Oncology and Therapy · 8
PDF
PMD17 Comparison of Market Access Routes of Digital Health Applications in France, Germany and the UK
2020 · L. Vollmer, G. Foxon, et al. · Value in Health · 4
PPM11 Market Access Landscape for Advanced Therapy Medicinal Products in the EU-5
2020 · F. Benazet, I. Berard, et al. · Value in Health · 3
Pbi38 Innovative Atmps: Market Access and Reimbursement Decisions in the Eu5: Availability or Not, That Is the Question...
2019 · S. Walzer, M. Prada, et al. · Value in Health · 3
PDF
Pro72 Market Access, Pricing and Reimbursement Processes for Orphan Drugs in the Eu-5 Countries: a Comparative Assessment
2019 · L. Vollmer, M. Prada, et al. · Value in Health · 2
PDF
A Comparison of Market Access Evaluations for Type Ii Diabetes Mellitus In France and Germany: An Analysis Using The Prismaccess Database
2015 · D Droeschel, B de Paz, et al. · Value in Health · 2
HPR148 Navigating Three Systems: A Comparative Analysis of Pharmaceutical Reimbursement in Germany, Austria, and Switzerland
2025 · Stefan Walzer, Jonas Jost, et al. · Value in Health · 1
Epidemiology of Parkinson's Disease in Germany Between 2016 and 2021 Based on Statutory Health Insurance Claims Data
2025 · Dirk Woitalla, Gisa Ellrichmann, et al. · Brain and Behavior · 1
PDF
Reimbursement and Pricing
2022 · Stefan Walzer, Roman Spelsberg, et al. · Contributions to economics · 1
PRO65 Time to Reimbursement for Orphan Drugs in EU5 in the Last FIVE YEARS
2020 · E. Molchanova, F. Benazet, et al. · Value in Health · 1
Pro80 Comparison of Early Access Programmes for Orphan Drugs in the Eu-5 Countries
2019 · W. Schleich, L. Vollmer, et al. · Value in Health · 1
Pam3 Individualized Nutritional Support in Medical Inpatients Results in Cost Savings: Economic Evaluation of the Effort Trial
2019 · P. Schuetz, S. Sulo, et al. · Value in Health · 1
PDF
Nothing Ventured, Nothing Gained – Is The Innovation Fund The Catapult to A New Generation of Care Concepts and A Competitive Market in Health Care in Germany?
2016 · D Droeschel, L Vollmer, et al. · Value in Health · 1
A Systematic Comparision of Iqwig Recommendations and G-Ba Decisions In The Amnog Process In Germany
2015 · L Vollmer, D Dröschel, et al. · Value in Health · 1
Are Vaccinations Really Different to Pharmaceuticals With Respect to Market Access In Germany?
2015 · D Droeschel, L Vollmer, et al. · Value in Health · 1
OP20 Qualitative Insights Into Artificial Intelligence (AI) and Virtual Reality (VR) Training for Value Communication: Comparing Innovative Technologies With Traditional Methods in Pharma
2025 · Stefan Walzer, Rodrigo Silva, et al. · Value in Health
PDF
HPR171 Reframing Pharmaceutical Pricing: Implications of the 2025 SVR Report for Germany’s Pricing Logic and International Spillovers
2025 · Stefan Walzer, Lutz Michael Vollmer, et al. · Value in Health
HPR217 Three Systems, One Market? A Comparative Analysis of Medical Device Reimbursement in Germany, Austria, and Switzerland
2025 · Stefan Walzer, Jonas Jost, et al. · Value in Health
HTA228 Market Access 2030: AI-Driven Dossier Transformation and Therapeutic Value Communication Across Global Health Systems
2025 · Stefan Walzer, Helmut Butscher, et al. · Value in Health
Epidemiology of Parkinson's Disease in Germany Between 2016 and 2021 Based on Statutory Health Insurance Claims Data
2025 · Vollmer, Lutz-Michael · Universitätsbibliothek Tübingen
HTA113 Comparative Analysis of Traditional vs AI-Assisted Health Technology Assessment Dossier Writing
2024 · J Jost, S Walzer, et al. · Value in Health
HTA84 Validation of the AI-Based Early Reimbursement Planning Search Engine in Main European Countries and the USA
2024 · A Billstein, S Walzer, et al. · Value in Health
PDF
Works count: 54
Citation count: 222
H-index: 4
I10-index: 3
Year
Topic
Type